IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Gigamon Inc. and Encourages Investors with Losses to Contact the Firm

Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Gigamon Inc. (“Gigamon” or the “Company”) (NYSE: GIMO) concerning possible violations of federal securities laws.

To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.

The investigation is centered on whether Gigamon and some of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

Gigamon is involved with products and services that provide customers visibility and power over network traffic for corporations and service providers in the United States, as well as various international locations.

On January 18, 2017, Gigamon announced early fourth quarter and fiscal year 2016 results. In the report, Gigamon revealed that fourth quarter revenue for the period ending December 31, 2016 would be significantly less compared to the guidance last year.

The Company claimed fourth quarter revenue fell short because of “lower than expected product booking” as well as the decision of existing customers to hold “purchasing decisions into 2017.” When this information was revealed to the public, the value of Gigamon stock fell over 28%, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.